Clinical trial
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab…
NCT00310128 · AIDS Malignancy Consortium, Other · Withdrawn
Key facts
| NCT number | NCT00310128 |
|---|---|
| Title | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma |
| Official title | Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma |
| Lead sponsor | AIDS Malignancy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | cisplatin, cytarabine, etoposide, methylprednisolone, rituximab, yttrium Y 90 ibritumomab tiuxetan, antibody therapy, biological therapy, chemotherapy, monoclonal antibody therapy and 3 more |
| Enrollment | 0 |
| Start date | Feb 1, 2006 |
| First posted | Apr 3, 2006 |
| Last update posted | Feb 3, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: